Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amimaitosai Injection Combined With Corticosteroids for Gastrointestinal Acute GVHD
NCT07803978Phase 1Enrolling by invitation
- Sponsor
- Chinese PLA General Hospital
- Start
- May 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in acute gastrointestinal graft-versus-host disease (aGI-GVHD) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Overall Response Rate at 28 days. Started May 2026; status: enrolling by invitation.
02
Conditions
acute gastrointestinal graft-versus-host disease (aGI-GVHD)
Beyond the preview
Go deeper on NCT07803978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07803978.